Use of rituximab, the new FDA-approved antibody

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 548-551

  Leget, Gail A ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER; CHIMERA; CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031785720     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00012     Document Type: Short Survey

References (29)

1. Landis S, Murray T, Bolden S, Wingo P: Cancer Statistics. CA Cancer J Clin 1998, 48:6-29.
2. Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, et al.: Lymphoma classification proposai: clarification. Blood 1995, 85:857-860.
3. Anderson K, Bates M, Slaughenhoupt B, Pinkus G, Schlossman S, Nadler L: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424-1433.
4. Aisenberg A: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:2656-2675.
5. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20(suppl 5):75-88.
6. Rosenberg S, Berard C, Brown J, Burke J, Dorfman R, Glatstein E, et al.: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage: the Non-Hodgkins Lymphoma Pathologic Classification Project. Cancer 1982, 49:2112-2135.
7. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al.: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993, 329:459-465.
8. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al.: Iodine-131 -anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996, 14:1974-1981.
9. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497. This paper is of historical interest. It is the original paper which describes the development of monoclonal antibodies.
10. Nadler L, Stashenko P, Hardy R, Kaplan W, Button L, Kufe D, et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147-3154.
11. 1 protein. J Biol Chem 1997, 272:14733-14739.
12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
13. Rituximab [package insert]. La Jolla, CA: IDEC Pharmaceuticals, and South San Francisco, CA: Genentech; 1997.
14. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines [abstract]. Blood 1996, 88:637.
15. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186. This paper investigates multiple mechanisms in which the C2B8 antibody enhances drug cytotoxicity.
16. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:4257-4266.
17. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al.: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
18. Maloney DG, Grillo-Lopez AJ, Bodkin D, White C, Foon K, Shcilder RF, et al.: IDEC-C2B8 anti-CD20 antibody: results of long-term follow-up of relapsed NHL phase II trial patients [abstract]. Blood 1995, 86(suppl 1):54.
19. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Shilker RF, Neidhart JA, et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
20. McLaughlin P, Cabanillas F, Grillo-Lopez AJ, Link BK, Levy R, Czuczman M, et al.: IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients (Rs) with relapsed low-grade or follicular lymphoma (LG/F NHL) [abstract]. Blood 1996, 88(suppl 1):90.
21. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Cohen R, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
22. Grillo-Lopez AJ, Horning S, Cheson BD, Peterson B, Coiffier B, Hagenbeek A, et al.: Development of response criteria (RC) for low-grade or follicular lymphomas (LG/F NHL) and application in a 166 patient study. Exp Hematol 1997, 25:732.
23. Almasri NM, Duque RE, Iturraspe J, Everette E, Braylan RC: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992, 40:259-263.
24. Czuczman MS, Grillo-Lopez AJ, Jonas C, Gordon L, Salch M, White CA, et al.: IDEC-C2B8 and CHOP chemoimmunotherapy of low-grade lymphoma [abstract]. Blood 1995, 86(suppl 1):55.
25. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al.: The treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody (Rituxan, Rituximab) and CHOP chemotherapy. J Clin Oncol 1998, in press.
26. Coiffier B, Ketterer N, Haioun C, Reyes F, Diehl V, Tilly H, et al.: A multicenter, randomized phase II study of rituximab (chimeric anti-CD20 mAb) at two dosages in patients with relapsed or refractory intermediate or high-grade NHL (IHG-NHL) or in elderly patients in first-line therapy [abstract]. Blood 1997, 90:510.
27. Link BK, Grossbard ML, Fisher RI, Czuczman M, Gilman P, Lowe AM, Vose JM: Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL [abstract]. Proc Am Soc Clin Oncol 1998, 17:3.
28. Davis T, Maloney D, White CA, Grillo-Lopez AJ, Williams M, Weiner G, et al.: Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkins lymphoma (NHL) with rituximab and alpha interferon [abstract]. Proc Am Soc Clin Oncol 1998, 17:11.
29. Van der Kolk LE, Gerritsen W, Baars J, Jonkhoff AR, van Oers MHJ: Phase I/II clinical trial to evaluate the safety and efficacy of a combination of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma [abstract]. Blood 1997, 90:512-513.